Codex DNA (DNAY) IPO Prices at $16

Codex DNA, Inc. (NASDAQ: DNAY) announced the pricing of its initial public offering of 6,666,665 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Codex DNA.

Jefferies LLC, Cowen and Company, LLC and KeyBanc Capital Markets Inc. are acting as joint book-running managers for the proposed offering.

Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Codex DNA’s solution is the BioXp™ system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. Codex DNA believes the BioXp™ system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.

You May Also Be Interested In

• SpaceX prices historic IPO at $135/share in largest ever new listing
• TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'
• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut